230 related articles for article (PubMed ID: 36200137)
1. Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
Park H; Kang HR; Huang PL; Lo-Ciganic WH; DeRemer CE; Wilson D; Dietrich EA
Clin Transl Sci; 2023 Jan; 16(1):128-139. PubMed ID: 36200137
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
Kang HR; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Park H
Clin Pharmacol Ther; 2022 Jul; 112(1):133-145. PubMed ID: 35420702
[TBL] [Abstract][Full Text] [Related]
3. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
4. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
5. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
6. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
Adv Ther; 2021 Nov; 38(11):5519-5533. PubMed ID: 34570310
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study.
Ellenbogen MI; Ardeshirrouhanifard S; Segal JB; Streiff MB; Deitelzweig SB; Brotman DJ
J Hosp Med; 2022 Oct; 17(10):809-818. PubMed ID: 35929542
[TBL] [Abstract][Full Text] [Related]
11. Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients Receiving Long-Term Dialysis.
Wetmore JB; Herzog CA; Yan H; Reyes JL; Weinhandl ED; Roetker NS
Clin J Am Soc Nephrol; 2022 May; 17(5):693-702. PubMed ID: 35470214
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
Cohen AT; Sah J; Dhamane AD; Hines DM; Lee T; Rosenblatt L; Emir B; Keshishian A; Yuce H; Luo X
Adv Ther; 2023 Apr; 40(4):1705-1735. PubMed ID: 36811795
[TBL] [Abstract][Full Text] [Related]
15. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
Weycker D; Wygant GD; Guo JD; Lee T; Luo X; Rosenblatt L; Mardekian J; Atwood M; Hanau A; Cohen AT
Blood Adv; 2020 Jan; 4(2):432-439. PubMed ID: 31990332
[TBL] [Abstract][Full Text] [Related]
16. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
17. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study.
Glise Sandblad K; Schulman S; Rosengren A; Sörbo J; Philipson J; Hansson PO
J Intern Med; 2023 Dec; 294(6):743-760. PubMed ID: 37641391
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Delinger R; Yuce H; Luo X
Thromb Haemost; 2022 Jun; 122(6):926-938. PubMed ID: 34963185
[TBL] [Abstract][Full Text] [Related]
20. Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.
Kang HR; Jones BL; Lo-Ciganic WH; DeRemer CE; Dietrich EA; Huang PL; Wilson DL; Park H
J Manag Care Spec Pharm; 2023 Nov; 29(11):1219-1230. PubMed ID: 37889866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
